Logo image of AYTU

AYTU BIOPHARMA INC (AYTU) Stock Fundamental Analysis

NASDAQ:AYTU - Nasdaq - US0547548588 - Common Stock - Currency: USD

1.34  -0.01 (-0.74%)

After market: 1.33 -0.01 (-0.75%)

Fundamental Rating

3

Overall AYTU gets a fundamental rating of 3 out of 10. We evaluated AYTU against 198 industry peers in the Pharmaceuticals industry. AYTU has a bad profitability rating. Also its financial health evaluation is rather negative. AYTU has a correct valuation and a medium growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year AYTU has reported negative net income.
In the past year AYTU had a positive cash flow from operations.
AYTU had negative earnings in each of the past 5 years.
In the past 5 years AYTU always reported negative operating cash flow.
AYTU Yearly Net Income VS EBIT VS OCF VS FCFAYTU Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

The Return On Assets of AYTU (-4.51%) is better than 73.74% of its industry peers.
With a decent Return On Equity value of -17.04%, AYTU is doing good in the industry, outperforming 72.73% of the companies in the same industry.
Industry RankSector Rank
ROA -4.51%
ROE -17.04%
ROIC N/A
ROA(3y)-35%
ROA(5y)-27.17%
ROE(3y)-112.19%
ROE(5y)-78.65%
ROIC(3y)N/A
ROIC(5y)N/A
AYTU Yearly ROA, ROE, ROICAYTU Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400 -500

1.3 Margins

AYTU's Gross Margin of 67.43% is fine compared to the rest of the industry. AYTU outperforms 72.73% of its industry peers.
AYTU's Gross Margin has been stable in the last couple of years.
AYTU does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 67.43%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y14.82%
GM growth 5Y-0.72%
AYTU Yearly Profit, Operating, Gross MarginsAYTU Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K -2K -2.5K

More info and screens

2

2. Health

2.1 Basic Checks

AYTU does not have a ROIC to compare to the WACC, probably because it is not profitable.
AYTU has more shares outstanding than it did 1 year ago.
The number of shares outstanding for AYTU has been increased compared to 5 years ago.
Compared to 1 year ago, AYTU has a worse debt to assets ratio.
AYTU Yearly Shares OutstandingAYTU Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M 4M 5M
AYTU Yearly Total Debt VS Total AssetsAYTU Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

AYTU has an Altman-Z score of -3.31. This is a bad value and indicates that AYTU is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -3.31, AYTU is in line with its industry, outperforming 44.44% of the companies in the same industry.
AYTU has a debt to FCF ratio of 29.85. This is a negative value and a sign of low solvency as AYTU would need 29.85 years to pay back of all of its debts.
AYTU has a better Debt to FCF ratio (29.85) than 76.26% of its industry peers.
A Debt/Equity ratio of 0.45 indicates that AYTU is not too dependend on debt financing.
AYTU has a Debt to Equity ratio (0.45) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 0.45
Debt/FCF 29.85
Altman-Z -3.31
ROIC/WACCN/A
WACC18.71%
AYTU Yearly LT Debt VS Equity VS FCFAYTU Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M

2.3 Liquidity

A Current Ratio of 0.98 indicates that AYTU may have some problems paying its short term obligations.
AYTU's Current ratio of 0.98 is on the low side compared to the rest of the industry. AYTU is outperformed by 82.83% of its industry peers.
A Quick Ratio of 0.81 indicates that AYTU may have some problems paying its short term obligations.
AYTU has a worse Quick ratio (0.81) than 82.83% of its industry peers.
Industry RankSector Rank
Current Ratio 0.98
Quick Ratio 0.81
AYTU Yearly Current Assets VS Current LiabilitesAYTU Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

5

3. Growth

3.1 Past

AYTU shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 71.29%, which is quite impressive.
AYTU shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -30.18%.
Measured over the past years, AYTU shows a very strong growth in Revenue. The Revenue has been growing by 61.82% on average per year.
EPS 1Y (TTM)71.29%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-550%
Revenue 1Y (TTM)-30.18%
Revenue growth 3Y7.28%
Revenue growth 5Y61.82%
Sales Q2Q%-29.27%

3.2 Future

The Earnings Per Share is expected to grow by 35.64% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 9.72% on average over the next years. This is quite good.
EPS Next Y125.68%
EPS Next 2Y57.75%
EPS Next 3Y35.64%
EPS Next 5YN/A
Revenue Next Year-17.49%
Revenue Next 2Y-5.54%
Revenue Next 3Y-3.13%
Revenue Next 5Y9.72%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
AYTU Yearly Revenue VS EstimatesAYTU Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 50M 100M
AYTU Yearly EPS VS EstimatesAYTU Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 -50K -100K -150K

More info and screens

6

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for AYTU. In the last year negative earnings were reported.
The Price/Forward Earnings ratio is 0.96, which indicates a rather cheap valuation of AYTU.
Compared to the rest of the industry, the Price/Forward Earnings ratio of AYTU indicates a rather cheap valuation: AYTU is cheaper than 99.49% of the companies listed in the same industry.
AYTU is valuated cheaply when we compare the Price/Forward Earnings ratio to 20.77, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 0.96
AYTU Price Earnings VS Forward Price EarningsAYTU Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

AYTU's Price/Free Cash Flow ratio is rather cheap when compared to the industry. AYTU is cheaper than 86.36% of the companies in the same industry.
Industry RankSector Rank
P/FCF 15.57
EV/EBITDA -0.1
AYTU Per share dataAYTU EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

AYTU's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as AYTU's earnings are expected to grow with 35.64% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y57.75%
EPS Next 3Y35.64%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for AYTU!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AYTU BIOPHARMA INC

NASDAQ:AYTU (5/1/2025, 6:19:26 PM)

After market: 1.33 -0.01 (-0.75%)

1.34

-0.01 (-0.74%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-12 2025-02-12/amc
Earnings (Next)05-19 2025-05-19
Inst Owners30.53%
Inst Owner Change0.93%
Ins Owners2.35%
Ins Owner Change0.23%
Market Cap8.27M
Analysts82.86
Price Target8.16 (508.96%)
Short Float %1.98%
Short Ratio3.26
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)117.92%
Min EPS beat(2)8.96%
Max EPS beat(2)226.87%
EPS beat(4)3
Avg EPS beat(4)44.38%
Min EPS beat(4)-78.65%
Max EPS beat(4)226.87%
EPS beat(8)5
Avg EPS beat(8)-428.35%
EPS beat(12)7
Avg EPS beat(12)-308.14%
EPS beat(16)8
Avg EPS beat(16)-261.19%
Revenue beat(2)2
Avg Revenue beat(2)10.13%
Min Revenue beat(2)2.24%
Max Revenue beat(2)18.02%
Revenue beat(4)3
Avg Revenue beat(4)4.57%
Min Revenue beat(4)-3.7%
Max Revenue beat(4)18.02%
Revenue beat(8)5
Avg Revenue beat(8)-1.48%
Revenue beat(12)7
Avg Revenue beat(12)-0.12%
Revenue beat(16)8
Avg Revenue beat(16)-1.05%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-189.47%
EPS NY rev (1m)0%
EPS NY rev (3m)20%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-21.88%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-4.61%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 0.96
P/S 0.12
P/FCF 15.57
P/OCF 12.29
P/B 0.27
P/tB N/A
EV/EBITDA -0.1
EPS(TTM)-1.16
EYN/A
EPS(NY)1.4
Fwd EY104.28%
FCF(TTM)0.09
FCFY6.42%
OCF(TTM)0.11
OCFY8.14%
SpS11.14
BVpS4.99
TBVpS-3.11
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -4.51%
ROE -17.04%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 67.43%
FCFM 0.77%
ROA(3y)-35%
ROA(5y)-27.17%
ROE(3y)-112.19%
ROE(5y)-78.65%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y14.82%
GM growth 5Y-0.72%
F-Score5
Asset Turnover0.59
Health
Industry RankSector Rank
Debt/Equity 0.45
Debt/FCF 29.85
Debt/EBITDA 5.94
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion 28.57%
Profit Quality N/A
Current Ratio 0.98
Quick Ratio 0.81
Altman-Z -3.31
F-Score5
WACC18.71%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)71.29%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-550%
EPS Next Y125.68%
EPS Next 2Y57.75%
EPS Next 3Y35.64%
EPS Next 5YN/A
Revenue 1Y (TTM)-30.18%
Revenue growth 3Y7.28%
Revenue growth 5Y61.82%
Sales Q2Q%-29.27%
Revenue Next Year-17.49%
Revenue Next 2Y-5.54%
Revenue Next 3Y-3.13%
Revenue Next 5Y9.72%
EBIT growth 1Y3.24%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year596.71%
EBIT Next 3Y126.9%
EBIT Next 5YN/A
FCF growth 1Y101.91%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y102.42%
OCF growth 3YN/A
OCF growth 5YN/A